De novo Drug Design using Reinforcement Learning with Multiple GPT Agents
Fuente:
arXiv
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Preprint |
| Published: |
2023
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1866914638946369536 |
|---|---|
| author | Hu, Xiuyuan Liu, Guoqing Zhao, Yang Zhang, Hao |
| author_facet | Hu, Xiuyuan Liu, Guoqing Zhao, Yang Zhang, Hao |
| contents | De novo drug design is a pivotal issue in pharmacology and a new area of focus in AI for science research. A central challenge in this field is to generate molecules with specific properties while also producing a wide range of diverse candidates. Although advanced technologies such as transformer models and reinforcement learning have been applied in drug design, their potential has not been fully realized. Therefore, we propose MolRL-MGPT, a reinforcement learning algorithm with multiple GPT agents for drug molecular generation. To promote molecular diversity, we encourage the agents to collaborate in searching for desirable molecules in diverse directions. Our algorithm has shown promising results on the GuacaMol benchmark and exhibits efficacy in designing inhibitors against SARS-CoV-2 protein targets. The codes are available at: https://github.com/HXYfighter/MolRL-MGPT. |
| format | Preprint |
| id |
arxiv_https___arxiv_org_abs_2401_06155 |
| institution | arXiv |
| publishDate | 2023 |
| record_format | arxiv |
| spellingShingle | De novo Drug Design using Reinforcement Learning with Multiple GPT Agents Hu, Xiuyuan Liu, Guoqing Zhao, Yang Zhang, Hao Biomolecules Computational Engineering, Finance, and Science Machine Learning De novo drug design is a pivotal issue in pharmacology and a new area of focus in AI for science research. A central challenge in this field is to generate molecules with specific properties while also producing a wide range of diverse candidates. Although advanced technologies such as transformer models and reinforcement learning have been applied in drug design, their potential has not been fully realized. Therefore, we propose MolRL-MGPT, a reinforcement learning algorithm with multiple GPT agents for drug molecular generation. To promote molecular diversity, we encourage the agents to collaborate in searching for desirable molecules in diverse directions. Our algorithm has shown promising results on the GuacaMol benchmark and exhibits efficacy in designing inhibitors against SARS-CoV-2 protein targets. The codes are available at: https://github.com/HXYfighter/MolRL-MGPT. |
| title | De novo Drug Design using Reinforcement Learning with Multiple GPT Agents |
| topic | Biomolecules Computational Engineering, Finance, and Science Machine Learning |
| url | https://arxiv.org/abs/2401.06155 |